A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer ...

PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments ... and more than 200 others are making their way through (pre)clinical phases. 1 However, the ability of these ...

Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and ... tumours that carry BRCA 1/2 mutations.

Figure 1: Domain architecture of the classic ... mono-ADP-ribosyltransferase PARP10. Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

The drug will slot in alongside other R&D programmes at Merck, investigating inhibitors of DNA damage response that, along with PARP ... BRCA1/2, PALB2, or RAD51C mutations, in the phase 1/2 ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...